# Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)

> **NCT00129805** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 1510 (actual)

## Conditions studied

- Cerebral Infarction

## Interventions

- **DRUG:** MCI-9042
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT00129805
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 1510 (ACTUAL)
- **Last updated:** 2008-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129805, "Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00129805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*